- Home
- CRBP vs TIL Comparison
CRBP vs TIL Comparison
Compare CRBP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- TIL
- Stock Information
- Founded
- CRBP 2009
- TIL 2018
- Country
- CRBP United States
- TIL United States
- Employees
- CRBP 19
- TIL N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- TIL Health Care
- Exchange
- CRBP Nasdaq
- TIL Nasdaq
- Market Cap
- CRBP 158.3M
- TIL 134.5M
- IPO Year
- CRBP N/A
- TIL 2021
- Fundamental
- Price
- CRBP $13.00
- TIL $20.80
- Analyst Decision
- CRBP Strong Buy
- TIL Buy
- Analyst Count
- CRBP 8
- TIL 4
- Target Price
- CRBP $62.00
- TIL $100.33
- AVG Volume (30 Days)
- CRBP 313.3K
- TIL 110.1K
- Earning Date
- CRBP 11-07-2024
- TIL 11-13-2024
- Dividend Yield
- CRBP N/A
- TIL N/A
- EPS Growth
- CRBP N/A
- TIL N/A
- EPS
- CRBP N/A
- TIL N/A
- Revenue
- CRBP N/A
- TIL N/A
- Revenue This Year
- CRBP N/A
- TIL N/A
- Revenue Next Year
- CRBP N/A
- TIL $2.65
- P/E Ratio
- CRBP N/A
- TIL N/A
- Revenue Growth
- CRBP N/A
- TIL N/A
- 52 Week Low
- CRBP $5.25
- TIL $6.88
- 52 Week High
- CRBP $61.90
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- CRBP 25.10
- TIL 36.46
- Support Level
- CRBP $12.90
- TIL $19.01
- Resistance Level
- CRBP $16.21
- TIL $22.69
- Average True Range (ATR)
- CRBP 0.95
- TIL 2.53
- MACD
- CRBP -0.16
- TIL -0.27
- Stochastic Oscillator
- CRBP 1.69
- TIL 10.72
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.